Table 3.
Percentage of participants (n = 20) classified as “impaired” based on performance on the DRUID® application and field sobriety tests.
| Number (%) | 0 mg oral | 10 mg oral | 25 mg oral | 0 mg vaped | 5 mg vaped | 20 mg vaped |
|---|---|---|---|---|---|---|
|
| ||||||
| Impaired based on raw data scores | ||||||
| Walk and turna | 3 (15%) | 6 (30%) | 8 (40%) | 5 (25%) | 10 (50%) | 9 (45%) |
| One leg standa | 3 (15%) | 7 (35%) | 6 (30%) | 3 (15%) | 3 (15%) | 8 (40%) |
| Modified Romberg balancea | 4 (20%) | 6 (30%) | 7 (35%) | 6 (30%) | 7 (35%) | 11 (55%) |
| DRUIDb | 1 (5%) | 4 (20%) | 10 (50%)* | 2 (10%) | 3 (15%) | 9 (45%) |
| Impaired based on change-from-baseline scores | ||||||
| Walk and turna | 2 (10%) | 2 (10%) | 6 (30%) | 3 (15%) | 7 (35%) | 6 (30%) |
| One leg standa | 1 (5%) | 4 (20%) | 5 (25%) | 1 (5%) | 1 (5%) | 4 (20%) |
| Modified Romberg balancea | 2 (10%) | 3 (15%) | 4 (20%) | 1 (5%) | 2 (10%) | 7 (35%) |
| DRUIDc | 0 (0%) | 2 (10%) | 9 (45%)* | 0 (0%) | 2 (10%) | 7 (35%)* |
Significant difference from placebo within that route of administration (Bonferroni-corrected, p < 0.016); Δ = significant difference between low and high dose within that route of administration (Bonferroni-corrected, p < 0.016). McNemar’s tests were used for planned comparisons.
Impairment criteria:
⩾2 peak (or peak change-from-baseline) clues observed = “impaired”; <2 peak (or peak change-from-baseline) clues = “not impaired.”
⩾57 DRUID® global impairment score = “impaired”; <57 score = “not impaired.”
⩾13-point change (from baseline) on DRUID® global impairment score = “impaired”; <13-point change (from baseline) = “not impaired.”